Search

Your search keyword '"Olajide, Oludamilola"' showing total 26 results
Start Over Author "Olajide, Oludamilola"
26 results on '"Olajide, Oludamilola"'

1. A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

Author

Nakamura, Zev M., primary, Deal, Allison M., additional, Park, Eliza M., additional, Stanton, Kate E., additional, Lopez, Yesy E., additional, Quillen, Laura J., additional, O’Hare Kelly, Erin, additional, Heiling, Hillary M., additional, Nyrop, Kirsten A., additional, Ray, Emily M., additional, Dees, E. Claire, additional, Reeder‐Hayes, Katherine E., additional, Jolly, Trevor A., additional, Carey, Lisa A., additional, Abdou, Yara, additional, Olajide, Oludamilola A., additional, Rauch, Julia K., additional, Joseph, Ranjit, additional, Copeland, Anureet, additional, McNamara, Megan A., additional, Ahles, Tim A., additional, and Muss, Hyman B., additional

Published
2023
Full Text
View/download PDF

3. A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer.

Author

Nakamura, Zev, primary, Deal, Allison Mary, additional, Park, Eliza Myung, additional, Stanton, Kate, additional, Lopez, Yesy, additional, Quillen, Laura J., additional, Kelly, Erin O'Hare, additional, Heiling, Hillary M, additional, Nyrop, Kirsten A., additional, Ray, Emily Miller, additional, Dees, Elizabeth Claire, additional, Reeder-Hayes, Katherine Elizabeth, additional, Jolly, Trevor Augustus, additional, Carey, Lisa A., additional, Abdou, Yara, additional, Olajide, Oludamilola A., additional, McNamara, Megan Ann, additional, Ahles, Tim, additional, and Muss, Hyman B., additional

Published
2022
Full Text
View/download PDF

4. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Author

Anders, Carey K, primary, Woodcock, Mark G, additional, Van Swearingen, Amanda E D, additional, Moore, Dominic T, additional, Sambade, Maria J, additional, Laurie, Sonia, additional, Robeson, Alexander, additional, Kolupaev, Oleg, additional, Cuaboy, Luz A, additional, Garrett, Amy L, additional, McKinnon, Karen, additional, Cowens, Kristen, additional, Bortone, Dante, additional, Calhoun, Benjamin C, additional, Wilkinson, Alec D, additional, Carey, Lisa, additional, Jolly, Trevor, additional, Muss, Hyman, additional, Reeder-Hayes, Katherine, additional, Kaltman, Rebecca, additional, Jankowitz, Rachel, additional, Gudena, Vinay, additional, Olajide, Oludamilola, additional, Perou, Charles, additional, Dees, E Claire, additional, Vincent, Benjamin G, additional, and Serody, Jonathan S, additional

Published
2022
Full Text
View/download PDF

5. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

Author

Hertz, Daniel L., Snavely, Anna C., McLeod, Howard L., Walko, Christine M., Ibrahim, Joseph G., Anderson, Steven, Weck, Karen E., Magrinat, Gustav, Olajide, Oludamilola, Moore, Susan, Raab, Rachel, Carrizosa, Daniel R., Corso, Steven, Schwartz, Garry, Peppercorn, Jeffrey M., Evans, James P., Jones, David R., Desta, Zeruesenay, Flockhart, David A., Carey, Lisa A., and Irvin, William J., Jr

Published
2015
Full Text
View/download PDF

7. 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Author

Woodcock, Mark, primary, Anders, Carey, additional, Swearingen, Amanda Van, additional, Moore, Dominic, additional, Sambade, Maria, additional, Cuaboy, Luz, additional, Garrett, Amy, additional, McKinnon, Karen, additional, Cowens, Kristen, additional, Bortone, Dante, additional, Calhoun, Benjamin, additional, Carey, Lisa, additional, Dees, Claire, additional, Jolly, Trevor, additional, Muss, Hyman, additional, Reeder-Hayes, Katherine, additional, Kaltman, Rebecca, additional, Jankowitz, Rachel, additional, Gudena, Vinay, additional, Olajide, Oludamilola, additional, Perou, Charles, additional, Vincent, Benjamin, additional, and Serody, Jonathan, additional

Published
2020
Full Text
View/download PDF

11. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

Author

Hertz, Daniel L, Snavely, Anna C, McLeod, Howard L, Walko, Christine M, Ibrahim, Joseph G, Anderson, Steven, Weck, Karen E, Magrinat, Gustav, Olajide, Oludamilola, Moore, Susan, Raab, Rachel, Carrizosa, Daniel R, Corso, Steven, Schwartz, Garry, Peppercorn, Jeffrey M, Evans, James P, Jones, David R, Desta, Zeruesenay, Flockhart, David A, Carey, Lisa A, and Irvin, William J

Subjects
Adult, Aged, 80 and over, Antineoplastic Agents, Hormonal, Genotype, Middle Aged, digestive system, Tamoxifen, Young Adult, Phenotype, Cytochrome P-450 CYP2D6, Pharmacogenetics, Humans, Female, skin and connective tissue diseases, Alleles, Genetic Association Studies, Aged
Abstract

A prospectively enrolled patient cohort was used to assess whether the prediction of CYP2D6 phenotype activity from genotype data could be improved by reclassification of diplotypes or alleles.Three hundred and fifty-five patients receiving tamoxifen 20 mg were genotyped for CYP2D6 and tamoxifen metabolite concentrations were measured. The endoxifen : N-desmethly-tamoxifen metabolic ratio, as a surrogate of CYP2D6 activity, was compared across four diplotypes (EM/IM, EM/PM, IM/IM, IM/PM) that are typically collapsed into an intermediate metabolizer (IM) phenotype. The relative metabolic activity of each allele type (UM, EM, IM, and PM) and each EM and IM allele was estimated for comparison with the activity scores typically assigned, 2, 1, 0.5 and 0, respectively.Each of the four IM diplotypes have distinct CYP2D6 activity from each other and from the EM and PM phenotype groups (each P 0.05). Setting the activity of an EM allele at 1.0, the relative activities of a UM, IM and PM allele were 0.85, 0.67 and 0.52, respectively. The activity of the EM alleles were statistically different (P 0.0001), with the CYP2D6*2 allele (scaled activity = 0.63) closer in activity to an IM than an EM allele. The activity of the IM alleles were also statistically different (P = 0.014).The current systems for translating CYP2D6 genotype into phenotype are not optimally calibrated, particularly in regards to IM diplotypes and the *2 allele. Additional research is needed to improve the prediction of CYP2D6 activity from genetic data for individualized dosing of CYP2D6 dependent drugs.

Published
2015
Full Text
View/download PDF

12. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma

Author

Park, Steven I., primary, Grover, Natalie S., additional, Olajide, Oludamilola, additional, Asch, Adam S., additional, Wall, James G., additional, Richards, Kristy L., additional, Sobol, Anna L., additional, Deal, Allison M., additional, Ivanova, Anastasia, additional, Foster, Matthew C., additional, Muss, Hyman B., additional, and Shea, Thomas C., additional

Published
2016
Full Text
View/download PDF

13. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

Author

Hertz, Daniel L., primary, Deal, Allison, additional, Ibrahim, Joseph G., additional, Walko, Christine M., additional, Weck, Karen E., additional, Anderson, Steven, additional, Magrinat, Gustav, additional, Olajide, Oludamilola, additional, Moore, Susan, additional, Raab, Rachel, additional, Carrizosa, Daniel R., additional, Corso, Steven, additional, Schwartz, Garry, additional, Graham, Mark, additional, Peppercorn, Jeffrey M., additional, Jones, David R., additional, Desta, Zeruesenay, additional, Flockhart, David A., additional, Evans, James P., additional, McLeod, Howard L., additional, Carey, Lisa A., additional, and Irvin, William J., additional

Published
2016
Full Text
View/download PDF

15. In vivoassessment of the metabolic activity of CYP2D6 diplotypes and alleles

Author

Hertz, Daniel L., primary, Snavely, Anna C., additional, McLeod, Howard L., additional, Walko, Christine M., additional, Ibrahim, Joseph G., additional, Anderson, Steven, additional, Weck, Karen E., additional, Magrinat, Gustav, additional, Olajide, Oludamilola, additional, Moore, Susan, additional, Raab, Rachel, additional, Carrizosa, Daniel R., additional, Corso, Steven, additional, Schwartz, Garry, additional, Peppercorn, Jeffrey M., additional, Evans, James P., additional, Jones, David R., additional, Desta, Zeruesenay, additional, Flockhart, David A., additional, Carey, Lisa A., additional, and Irvin, William J., additional

Published
2015
Full Text
View/download PDF

16. Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity

Author

Hertz, Daniel L, primary, Snavely, Anna C, additional, McLeod, Howard L, additional, Walko, Christine M, additional, Ibrahim, Joseph G, additional, Anderson, Steven, additional, Weck, Karen E, additional, Rubin, Peter, additional, Olajide, Oludamilola, additional, Moore, Susan, additional, Raab, Rachel, additional, Carrizosa, Daniel R, additional, Corso, Steven, additional, Schwartz, Gary, additional, Peppercorn, Jeffrey M, additional, Evans, James P, additional, Desta, Zeruesenay, additional, Flockhart, David A, additional, Carey, Lisa A, additional, and Irvin, William J, additional

Published
2015
Full Text
View/download PDF

17. A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma

Author

Park, Steven I., primary, Richards, Kristy L., additional, Olajide, Oludamilola, additional, Reddy, Nishitha M, additional, Ghosh, Nilanjan, additional, Budde, Elizabeth E., additional, Foster, Matthew C., additional, Deal, Allison M., additional, Noe, Jeanne F., additional, Shea, Thomas C., additional, and Ansell, Stephen M., additional

Published
2014
Full Text
View/download PDF

18. A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy

Author

Patel, Jai N., primary, O'Neil, Bert H., additional, Deal, Allison M., additional, Ibrahim, Joseph G., additional, Sherrill, Gary B., additional, Olajide, Oludamilola A., additional, Atluri, Prashanti M., additional, Inzerillo, John J., additional, Chay, Christopher H., additional, McLeod, Howard L., additional, and Walko, Christine M., additional

Published
2014
Full Text
View/download PDF

19. Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?

Author

Hertz, Daniel Louis, primary, Snavely, Anna C., additional, Evans, James P, additional, Ibrahim, Joseph G, additional, Anderson, Steven M., additional, Friedman, Kenneth J, additional, Weck, Karen E, additional, Rubin, Peter, additional, Olajide, Oludamilola A., additional, Moore, Susan G., additional, Raab, Rachel Elizabeth, additional, Carrizosa, Daniel R., additional, Corso, Steven William, additional, Schwartz, Garry, additional, Peppercorn, Jeffrey M., additional, Graham, Mark, additional, Canale, Sean Thomas, additional, McLeod, Howard L., additional, Carey, Lisa A., additional, and Irvin, William Johnson, additional

Published
2014
Full Text
View/download PDF

20. A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Park, Steven I., primary, Richards, Kristy L., additional, Asch, Adam S., additional, Olajide, Oludamilola, additional, Deal, Allison M., additional, Ivanova, Anastasia, additional, Wall, James G., additional, Sobol, Anna L., additional, Foster, Matthew C., additional, Muss, Hyman B., additional, and Shea, Thomas C., additional

Published
2013
Full Text
View/download PDF

21. Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice.

Author

Patel, Jai Narendra, primary, Deal, Allison Mary, additional, O'Neil, Bert H., additional, Ibrahim, Joe, additional, Sherrill, Gary Bradley, additional, Davies, Janine Marie, additional, Bernard, Stephen A., additional, Goldberg, Richard M., additional, Olajide, Oludamilola A., additional, Atluri, Prashanti, additional, Inzerillo, John J., additional, McLeod, Howard L., additional, and Walko, Christine Marie, additional

Published
2013
Full Text
View/download PDF

22. Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Author

Irvin, William J., primary, Walko, Christine M., additional, Weck, Karen E., additional, Ibrahim, Joseph G., additional, Chiu, Wing K., additional, Dees, E. Claire, additional, Moore, Susan G., additional, Olajide, Oludamilola A., additional, Graham, Mark L., additional, Canale, Sean T., additional, Raab, Rachel E., additional, Corso, Steven W., additional, Peppercorn, Jeffrey M., additional, Anderson, Steven M., additional, Friedman, Kenneth J., additional, Ogburn, Evan T., additional, Desta, Zeruesenay, additional, Flockhart, David A., additional, McLeod, Howard L., additional, Evans, James P., additional, and Carey, Lisa A., additional

Published
2011
Full Text
View/download PDF

26. Pulmonary Hypertension in Sickle Cell Disease: The Role of Activated Blood Coagulation and Inflammation.

Author

Ataga, Kenneth I., Moore, Charity, Jones, Susan, Olajide, Oludamilola, Sohier, Cathy, Clark, Shantres, Whinna, Herbert C., Parise, Leslie V., Hinderliter, Alan, and Orringer, Eugene P.

Abstract

Introduction: Pulmonary hypertension (PHT) is a common complication of sickle cell disease (SCD). The pathogenesis of PHT in this setting is likely multifactorial. There is an abundance of evidence to suggest that the coagulation system is activated in patients with SCD. In addition, autopsy series have shown that an in situthrombotic arteriopathy is seen in the majority of SCD patients with PHT. The purpose of this study is to determine whether markers of thrombin generation, platelet activation and inflammation are associated with PHT in SCD patients.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results